Category: Clinical Trials
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
ALKOVE Clinical Trial: a 4th Generation TKI from Nuvalent
The Phase 1/2 trial of Nuvalent, Inc.’s NVL-655, the fourth generation ALK TKI, has begun at Sarah Cannon Research Institute in Nashville, soon to be followed by additional locations. Below is a brief summary of the trial, with connections to relevant websites for more information. For patients currently on Lorlatinib, NVL-655 provides a hope-filled option…
-
An Exciting New Clinical Trial for Those who Are Resistant to ALK Inhibitors Is Recruiting Soon
Those in the ALK community fear the day when progression occurs after Lorlatinib, the “last” ALK inhibitor available. Although there are effective treatments after Lorlatinib, there is no standard treatment. Without a specified FDA-approved treatment, people must face Lorlatinib resistance without knowing the best strategy. In the next few months, the ALKove-1 trial will begin…
-
What is YAP and its significance for ALK-positive cancer
In recent years, a signal pathway called HIPPO, which is important in angiogenesis (blood vessel growth), has become important for the ALK cancer realm. There has been accumulating evidence that a protein called YAP (Yes Associated Protein-1) can prevent TKI-resistant cells from developing resistance in vitro and in vivo (in laboratory experiments and in cell…
-
Clinical Trials Can Help Those with ALK Lung Cancer Get State of the Art Treatment
In this newsletter, we pay tribute to Linnea Olson, a 17-year ALK-positive lung cancer survivor. We lost her in November of 2021, but her legacy as a creative, kind, and impactful lung cancer advocate will always inspire our group. Linnea, along with many other long-term ALK-positive lung cancer survivors, participated in clinical trials at several…
-
Announcing ALK Positive ClinWiki, A Better Way to Search for Clinical Trials
The main register of worldwide clinical trials is ClinicalTrials.gov, which has a search function. But searching for “ALK lung cancer” on ClinicalTrials.gov is a frustrating exercise. Oddly, you will be directed to many studies that exclude ALK lung cancer. The ALK lung cancer trials in ClinicalTrials.gov are not sorted by line of treatment, so it…
-
ALK-positive Clinical Trials are not just for people in the United States
If you are at diagnosis or at a juncture in treatment, an ALK-positive lung cancer clinical trial may help you receive state of the art treatment. Although many clinical trials for ALK-positive lung cancer have sites in the US, ALK Positives around the world have multiple clinical trial options. An exciting trial outside the US…
-
Are there any new Clinical Trials recruiting for ALK-positive lung cancer?
Clinical trials for more advanced ALK inhibitors, like the TPX-131 study recruiting in Australia and the US, are exciting because they improve on drugs we know work well for ALK-positive lung cancer. However most clinical trials of new ALK treatments in the US and Europe involve combination therapies, designed to overcome ALK inhibitor resistance. As…
-
Update on Clinical Trials currently recruiting for ALK-positive lung cancer
A new ALK inhibitor starts its clinical trials this month! TPX-0131 is an TKI ALK inhibitor designed to overcome multiple ALK resistance mutations. This first-in-human trial for ALK-positive lung cancer is now recruiting near Perth, Australia. Other sites for the FORGE-1 trial will be added in Australia and the U.S. over the next few months.…
-
Update on ALK Clinical Trials currently recruiting and a caregiver’s perspective on why treatment at an NCI cancer center prolongs survival
Like all trips to the emergency room, this one was unexpected. But my husband was shocked and overwhelmed to hear he had stage 4 lung cancer. With tumors throughout his chest and in his brain, his prognosis seemed dismal. The oncologist assigned by the hospital did not ease our panic. His bedside manner was characterized…
-
ALK Positive funds two new clinical trials
November is Lung Cancer Awareness Month, which is a good time to reflect on our successes as an organization. In 2020, we were excited to announce that the ALK Positive/LUNGevity Research Fund will be funding clinical trials for the first time. It means that the money we have donated and raised is going directly toward…